Breaking News

BioLife Solutions Acquires Sexton Biotechnologies

Sexton supports cell and gene therapy manufacturing with two product lines; processing and handling solutions, and cell performance supplements.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioLife Solutions entered into a definitive agreement to acquire all outstanding shares of Sexton Biotechnologies, a provider of manufacturing services for the cell and gene therapy (CGT) industry, in a transaction valued at $30 million.   Sexton provides end-to-end services for emerging cell and gene therapy manufacturers. The acquisition expands Sexton’s ability to meet market demands for their innovative tools such as CellSeal cryogenic storage vials, the Signata CT-5, the industry&#8...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters